{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T00:23:33Z","timestamp":1790036613584,"version":"4.0.1"},"reference-count":39,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,10,20]],"date-time":"2025-10-20T00:00:00Z","timestamp":1760918400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Neurol."],"abstract":"<jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>Serum glial fibrillary acidic protein (sGFAP) is a promising biomarker, but its quantification mainly relies on SIMOA, a technology not widely available in clinical practice.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objectives<\/jats:title>\n                    <jats:p>\n                      To evaluate the analytical performance of two high-throughput automated platforms\u2014Alinity\n                      <jats:sup>\u00ae<\/jats:sup>\n                      i (Abbott) and Lumipulse\n                      <jats:sup>\u00ae<\/jats:sup>\n                      G1200 (Fujirebio)\u2014for sGFAP quantification.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      A retrospective longitudinal study included 107 serum samples from 23 MS patients. sGFAP was measured with SIMOA SR-X\n                      <jats:sup>\u00ae<\/jats:sup>\n                      , Lumipulse\n                      <jats:sup>\u00ae<\/jats:sup>\n                      G1200, and Alinity\n                      <jats:sup>\u00ae<\/jats:sup>\n                      i. Data were log-transformed. Agreement was assessed using Pearson correlations, Passing\u2013Bablok regression, Bland\u2013Altman analysis, and \u0394log correlations between visits. Longitudinal differences across platforms were tested with a linear mixed-effects model (platform as fixed effect, SIMOA as reference). Moreover, \u0394SIMOA was modeled against \u0394Lumipulse and \u0394Alinity, adjusting for \u0394EDSS, phenotype, relapses and new MRI lesions.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Passing\u2013Bablok regression yielded slopes of 0.85 (SIMOA\u2013Lumipulse), 0.81 (SIMOA\u2013Alinity), and 0.95 (Lumipulse\u2013Alinity), with intercepts of \u22120.32, \u22120.35, and \u22120.05. Mean log-biases were \u22120.622, \u22120.733, and 0.109. Correlations between log-means and log-differences were\n                      <jats:italic>r<\/jats:italic>\n                      \u202f=\u202f0.26 (\n                      <jats:italic>p<\/jats:italic>\n                      \u202f=\u202f0.006), 0.44 (\n                      <jats:italic>p<\/jats:italic>\n                      \u202f&amp;lt;\u202f0.0001), and 0.15 (\n                      <jats:italic>p<\/jats:italic>\n                      \u202f=\u202f0.13). The mixed-effects model showed no significant \u0394log differences relative to SIMOA (\n                      <jats:italic>p<\/jats:italic>\n                      \u202f&amp;gt;\u202f0.1). When modeling \u0394SIMOA, \u0394Lumipulse was a significant predictor (\n                      <jats:italic>\u03b2<\/jats:italic>\n                      \u202f=\u202f0.51;\n                      <jats:italic>p<\/jats:italic>\n                      \u202f=\u202f0.002), whereas \u0394Alinity showed only a trend (\n                      <jats:italic>\u03b2<\/jats:italic>\n                      \u202f=\u202f0.31;\n                      <jats:italic>p<\/jats:italic>\n                      \u202f=\u202f0.051). No clinical covariates were significantly associated.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Automated platforms, particularly Lumipulse, showed strong concordance with SIMOA supporting the role in analytical monitoring.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fneur.2025.1682198","type":"journal-article","created":{"date-parts":[[2025,10,20]],"date-time":"2025-10-20T04:14:03Z","timestamp":1760933643000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":5,"title":["Cross-platform analytical assessment of serum GFAP quantification in multiple sclerosis: SIMOA versus two automated immunoassays"],"prefix":"10.3389","volume":"16","author":[{"given":"Jordi","family":"Tortosa-Carreres","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Cubas-N\u00fa\u00f1ez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J\u00e9ssica","family":"Castillo-Villalba","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lorena","family":"For\u00e9s-Toribio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raquel","family":"Gasque-Rubio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carlos","family":"Quintanilla-Bordas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carmen","family":"Alcal\u00e0-Vicente","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sara","family":"Carratal\u00e0-Bosc\u00e0","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana","family":"Va\u00f1o-Bellver","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bego\u00f1a","family":"Laiz-Marro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francisco Carlos","family":"P\u00e9rez-Miralles","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bonaventura","family":"Casanova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2025,10,20]]},"reference":[{"key":"ref1","doi-asserted-by":"publisher","first-page":"e16226","DOI":"10.1111\/jnc.16226","article-title":"The GFAP proteoform puzzle: how to advance GFAP as a fluid biomarker in neurological diseases","volume":"169","author":"Gogishvili","year":"2025","journal-title":"J Neurochem"},{"key":"ref2","doi-asserted-by":"publisher","first-page":"597","DOI":"10.3389\/fneur.2022.835597","article-title":"GFAP and S100B: what you always wanted to know and never dared to ask","volume":"13","author":"Janigro","year":"2022","journal-title":"Front Neurol"},{"key":"ref3","doi-asserted-by":"publisher","first-page":"108624","DOI":"10.1016\/j.intimp.2022.108624","article-title":"Serum glial fibrillary acidic protein is a body fluid biomarker: a valuable prognostic for neurological disease - a systematic review","volume":"107","author":"Heimfarth","year":"2022","journal-title":"Int Immunopharmacol"},{"key":"ref4","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1001\/jamaneurol.2022.5250","article-title":"Serum glial fibrillary acidic protein compared with Neurofilament light chain as a biomarker for disease progression in multiple sclerosis","volume":"80","author":"Meier","year":"2023","journal-title":"JAMA Neurol"},{"key":"ref5","doi-asserted-by":"publisher","first-page":"14798","DOI":"10.1038\/s41598-018-33158-8","article-title":"Serum GFAP as a biomarker for disease severity in multiple sclerosis","volume":"8","author":"Abdelhak","year":"2018","journal-title":"Sci Rep"},{"key":"ref6","doi-asserted-by":"publisher","first-page":"477","DOI":"10.1002\/acn3.51969","article-title":"Serum glial fibrillary acidic protein and disability progression in progressive multiple sclerosis","volume":"11","author":"Abdelhak","year":"2024","journal-title":"Ann Clin Transl Neurol"},{"key":"ref7","doi-asserted-by":"publisher","first-page":"102485","DOI":"10.1016\/j.arr.2024.102485","article-title":"CSF and blood glial fibrillary acidic protein for the diagnosis of Alzheimer\u2019s disease: a systematic review and meta-analysis","volume":"101","author":"Zou","year":"2024","journal-title":"Ageing Res Rev"},{"key":"ref8","doi-asserted-by":"publisher","first-page":"2790","DOI":"10.1002\/alz.12879","article-title":"Plasma glial fibrillary acidic protein in autosomal dominant Alzheimer\u2019s disease: associations with a\u03b2-PET, neurodegeneration, and cognition","volume":"19","author":"Chatterjee","year":"2023","journal-title":"Alzheimers Dement"},{"key":"ref9","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1093\/clinchem\/hvad018","article-title":"Plasma glial fibrillary acidic protein in the Alzheimer disease continuum: relationship to other biomarkers, differential diagnosis, and prediction of clinical progression","volume":"69","author":"Shen","year":"2023","journal-title":"Clin Chem"},{"key":"ref10","doi-asserted-by":"publisher","first-page":"e70034","DOI":"10.1111\/eci.70034","article-title":"New approach to specific Alzheimer\u2019s disease diagnosis based on plasma biomarkers in a cognitive disorder cohort","volume":"55","author":"\u00c1lvarez-S\u00e1nchez","year":"2025","journal-title":"Eur J Clin Investig"},{"key":"ref11","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1080\/1744666X.2023.2148657","article-title":"Glial fibrillary acidic protein as a biomarker in neuromyelitis optica spectrum disorder: a current review","volume":"19","author":"Schindler","year":"2023","journal-title":"Expert Rev Clin Immunol"},{"key":"ref12","doi-asserted-by":"publisher","first-page":"865730","DOI":"10.3389\/fneur.2022.865730","article-title":"Glial fibrillary acidic protein in blood as a disease biomarker of Neuromyelitis Optica Spectrum disorders","volume":"13","author":"Kim","year":"2022","journal-title":"Front Neurol"},{"key":"ref13","doi-asserted-by":"publisher","first-page":"13976","DOI":"10.3390\/ijms241813976","article-title":"Amyloid-Beta co-pathology is a major determinant of the elevated plasma GFAP values in amyotrophic lateral sclerosis","volume":"24","author":"Mastrangelo","year":"2023","journal-title":"Int J Mol Sci"},{"key":"ref14","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1007\/978-1-0716-4462-1_3","article-title":"Application of single molecule array (SIMOA) in cerebrospinal fluid","volume":"2914","author":"Anaya-Cubero","year":"2025","journal-title":"Methods Mol Biol Clifton NJ"},{"key":"ref15","doi-asserted-by":"publisher","first-page":"125529","DOI":"10.1016\/j.talanta.2023.125529","article-title":"Advances in single molecule arrays (SIMOA) for ultra-sensitive detection of biomolecules","volume":"270","author":"Dong","year":"2024","journal-title":"Talanta"},{"key":"ref16","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1021\/acssensors.1c02232","article-title":"Detection of glial fibrillary acidic protein in patient plasma using on-Chip graphene field-effect biosensors, in comparison with ELISA and Single-molecule Array","volume":"7","author":"Xu","year":"2022","journal-title":"ACS Sens"},{"key":"ref17","doi-asserted-by":"publisher","first-page":"408","DOI":"10.1093\/brain\/awae368","article-title":"Plasma p-tau217 in Alzheimer\u2019s disease: Lumipulse and ALZpath SIMOA head-to-head comparison","volume":"148","author":"Pilotto","year":"2025","journal-title":"Brain J Neurol"},{"key":"ref18","doi-asserted-by":"publisher","first-page":"4594","DOI":"10.3390\/ijms25094594","article-title":"Assessment of the correlation and diagnostic accuracy between cerebrospinal fluid and plasma Alzheimer\u2019s disease biomarkers: a comparison of the Lumipulse and Simoa platforms","volume":"25","author":"Dakterzada","year":"2024","journal-title":"Int J Mol Sci"},{"key":"ref19","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1016\/j.neurobiolaging.2024.08.007","article-title":"Plasma p-tau181 and amyloid markers in Alzheimer\u2019s disease: a comparison between Lumipulse and SIMOA","volume":"143","author":"Quaresima","year":"2024","journal-title":"Neurobiol Aging"},{"key":"ref20","doi-asserted-by":"publisher","first-page":"1950913","DOI":"10.1155\/2024\/1950913","article-title":"Comparative assessment of Simoa and Lumipulse for measuring serum neurofilament light chain in multiple sclerosis patients","volume":"2024","author":"Gasque-Rubio","year":"2024","journal-title":"Acta Neurol Scand"},{"key":"ref21","doi-asserted-by":"publisher","first-page":"1376","DOI":"10.1515\/cclm-2023-1169","article-title":"Minor head injury in anticoagulated patients: performance of biomarkers S100B, NSE, GFAP, UCH-L1 and Alinity TBI in the detection of intracranial injury. A prospective observational study","volume":"62","author":"Menditto","year":"2024","journal-title":"Clin Chem Lab Med"},{"key":"ref22","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1080\/14737159.2024.2306876","article-title":"The game changer: UCH-L1 and GFAP-based blood test as the first marketed in vitro diagnostic test for mild traumatic brain injury","volume":"24","author":"Kobeissy","year":"2024","journal-title":"Expert Rev Mol Diagn"},{"key":"ref23","doi-asserted-by":"publisher","first-page":"1308","DOI":"10.1111\/acem.14366","article-title":"Accuracy of a rapid glial fibrillary acidic protein\/ubiquitin carboxyl-terminal hydrolase L1 test for the prediction of intracranial injuries on head computed tomography after mild traumatic brain injury","volume":"28","author":"Bazarian","year":"2021","journal-title":"Acad Emerg Med"},{"key":"ref24","doi-asserted-by":"publisher","first-page":"1402","DOI":"10.1515\/cclm-2025-0093","article-title":"Establishing sex- and age-related reference intervals of serum glial fibrillary acid protein measured by the fully automated lumipulse system","volume":"63","author":"Agnello","year":"2025","journal-title":"Clin Chem Lab Med"},{"key":"ref25","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1016\/S1474-4422(17)30470-2","article-title":"Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria","volume":"17","author":"Thompson","year":"2018","journal-title":"Lancet Neurol"},{"key":"ref26","doi-asserted-by":"publisher","first-page":"614","DOI":"10.1001\/jamaneurol.2025.0495","article-title":"Standardized definition of progression independent of relapse activity (PIRA) in relapsing-remitting multiple sclerosis","volume":"82","author":"M\u00fcller","year":"2025","journal-title":"JAMA Neurol"},{"key":"ref27","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1038\/s41582-021-00616-3","article-title":"Blood GFAP as an emerging biomarker in brain and spinal cord disorders","volume":"18","author":"Abdelhak","year":"2022","journal-title":"Nat Rev Neurol"},{"key":"ref28","doi-asserted-by":"publisher","first-page":"6295","DOI":"10.3390\/ijms25126295","article-title":"Tau, glial fibrillary acidic protein, and Neurofilament light chain as brain protein biomarkers in cerebrospinal fluid and blood for diagnosis of neurobiological diseases","volume":"25","author":"Park","year":"2024","journal-title":"Int J Mol Sci"},{"key":"ref29","doi-asserted-by":"publisher","first-page":"1667","DOI":"10.1093\/brain\/awae035","article-title":"Serum GFAP levels correlate with astrocyte reactivity, post-mortem brain atrophy and neurofibrillary tangles","volume":"147","author":"S\u00e1nchez-Juan","year":"2024","journal-title":"Brain"},{"key":"ref30","doi-asserted-by":"publisher","first-page":"e213438","DOI":"10.1212\/WNL.0000000000213438","article-title":"Association of plasma biomarkers with longitudinal atrophy and microvascular burden on MRI across neurodegenerative and cerebrovascular diseases","volume":"104","author":"Sanchez","year":"2025","journal-title":"Neurology"},{"key":"ref31","doi-asserted-by":"publisher","first-page":"102340","DOI":"10.1016\/j.ceb.2024.102340","article-title":"GFAP-isoforms in the nervous system: understanding the need for diversity","volume":"87","author":"de Reus","year":"2024","journal-title":"Curr Opin Cell Biol"},{"key":"ref32","doi-asserted-by":"publisher","first-page":"7808","DOI":"10.3390\/ijms25147808","article-title":"Establishing Normal serum values of Neurofilament light chains and glial fibrillary acidic protein considering the effects of age and other demographic factors in healthy adults","volume":"25","author":"Rodero-Romero","year":"2024","journal-title":"Int J Mol Sci"},{"key":"ref33","doi-asserted-by":"publisher","first-page":"667","DOI":"10.1515\/cclm-2025-0667","article-title":"Method comparison of plasma and CSF GFAP immunoassays across multiple platforms","volume":"2025","author":"Arslan","year":"2025","journal-title":"Clin Chem Lab Med"},{"key":"ref34","doi-asserted-by":"publisher","first-page":"e209651","DOI":"10.1212\/WNL.0000000000209651","article-title":"Age-dependent differences in blood levels of glial fibrillary acidic protein but not ubiquitin Carboxy-terminal hydrolase L1 in children","volume":"103","author":"Mannix","year":"2024","journal-title":"Neurology"},{"key":"ref35","doi-asserted-by":"publisher","first-page":"e0135886","DOI":"10.1371\/journal.pone.0135886","article-title":"Levels and age dependency of Neurofilament light and glial fibrillary acidic protein in healthy individuals and their relation to the brain parenchymal fraction","volume":"10","author":"V\u00e5gberg","year":"2015","journal-title":"PLoS One"},{"key":"ref36","doi-asserted-by":"publisher","first-page":"474","DOI":"10.1093\/clinchem\/hvae002","article-title":"Clinical decision support in laboratory medicine","volume":"70","author":"Choy","year":"2024","journal-title":"Clin Chem"},{"key":"ref37","doi-asserted-by":"publisher","first-page":"e14535","DOI":"10.1002\/alz.14535","article-title":"Novel plasma biomarkers of amyloid plaque pathology and cortical thickness: evaluation of the NULISA targeted proteomic platform in an ethnically diverse cohort","volume":"21","author":"Zeng","year":"2025","journal-title":"Alzheimers Dement"},{"key":"ref38","doi-asserted-by":"publisher","first-page":"917","DOI":"10.3171\/2024.1.JNS232569","article-title":"Early GFAP and UCH-L1 point-of-care biomarker measurements for the prediction of traumatic brain injury and progression in patients with polytrauma and hemorrhagic shock","volume":"141","author":"Sperry","year":"2024","journal-title":"J Neurosurg"},{"key":"ref39","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1089\/neur.2020.0037","article-title":"Comparison of GFAP and UCH-L1 measurements from two prototype assays: the Abbott i-STAT and ARCHITECT assays","volume":"2","author":"Korley","year":"2021","journal-title":"Neurotrauma Rep"}],"container-title":["Frontiers in Neurology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fneur.2025.1682198\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,20]],"date-time":"2025-10-20T04:14:03Z","timestamp":1760933643000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fneur.2025.1682198\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,20]]},"references-count":39,"alternative-id":["10.3389\/fneur.2025.1682198"],"URL":"https:\/\/doi.org\/10.3389\/fneur.2025.1682198","relation":{},"ISSN":["1664-2295"],"issn-type":[{"value":"1664-2295","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,20]]},"article-number":"1682198"}}